Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03459-7Source: DataRank Database

Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12 is a research paper published in Cancer Immunology Immunotherapy (2023). On theSindex it has a DataRank of 0.312. It has been cited 7 times.

N/A

0.312DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.80)OA: hybridTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.312

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (11)

Ginette S. Santiago-Sánchez ORCID,Kellsye P. Fabian ORCID,Kristen Solocinski,Paul L. Chariou ORCID,Duane H. Hamilton ORCID

Live enrichment

PubMed:37166485 PMC:PMC10361896 OpenAlex:https://openalex.org/W4376131348

National Institutes of Health

Grant: ZIA BC 010944

Intramural NIH HHS

Grant: Z01 BC010944

National Institutes of Health

Grant: 1ZIABC010944-10

Strategies for Cancer Immunotherapy Development: Preclinical Studies

FWCI

0.80

Citation Percentile

0.7%

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://link.springer.com/content/pdf/10.1007/s00262-023-03459-7.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00262-023-03459-7.pdf

publisherhttps://link.springer.com/article/10.1007/s00262-023-03459-7/fulltext.html

journalhttps://doi.org/10.1007/s00262-023-03459-7

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37166485

Fields of Study

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune cells in cancer03 medical and health sciences0302 clinical medicineMiceAnimalsDocetaxelB7-H1 AntigenCD8-Positive T-LymphocytesNeoplasmsInterleukin-12NecrosisTumor MicroenvironmentCell Line, TumorImmunotherapy

MeSH Terms

DocetaxelAnimalsImmunotherapyNecrosisNeoplasmsCD8-Positive T-LymphocytesInterleukin-12Cell Line, TumorMiceTumor MicroenvironmentB7-H1 Antigen

Keywords

DocetaxelTumor microenvironmentCancer researchCombination therapyMedicineTumor necrosis factor alphaImmunotherapyImmune systemImmunologyCancerInternal medicinenecrosisCombination ImmunotherapyRil-12Nhs-il-12ResearchCD8-Positive T-LymphocytesInterleukin-12B7-H1 AntigenMiceNeoplasmsCell Line, TumorAnimals

Sustainable Development Goals

SDG 0: Good health and well-being